Keyphrases
Multiple Myeloma
84%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
36%
Relapsed or Refractory multiple Myeloma
31%
Myeloma
19%
Multiple Myeloma Patients
18%
Carfilzomib
17%
Selinexor
16%
Lenalidomide
15%
Bortezomib
12%
Risk Stratification
12%
Newly Diagnosed multiple Myeloma
12%
High Risk
11%
Conditioning Regimen
10%
Progression-free Survival
10%
Pomalidomide
9%
Standard of Care
9%
Protease Inhibitors
8%
Clinical High Risk
8%
Triplet Regimen
8%
Previously Treated
8%
Escalating Dose
8%
Allogeneic Peripheral Blood Stem Cell Transplantation
8%
High-dose Melphalan
8%
Phase II Study
8%
Anti-CD38 Monoclonal Antibody
8%
Treatment Decisions
8%
Median Progression-free Survival
8%
Overall Response Rate
7%
High-risk Myeloma
7%
Adverse Events
6%
CD38
6%
Improved Outcomes
6%
Patients with COVID-19
6%
Thalidomide
6%
Dose Escalation
5%
Heavily Pretreated
5%
Ultra-high Risk
5%
Once-weekly
5%
Gene Expression Profiling
5%
Phase 1b Study
5%
Monoclonal Antibody
5%
Stem Cell Transplantation
5%
Medicine and Dentistry
Multiple Myeloma
92%
Autologous Stem Cell Transplantation
27%
Myeloma
23%
Dexamethasone
21%
Diseases
15%
Progression Free Survival
14%
Lenalidomide
13%
Selinexor
12%
Risk Stratification
12%
Proteasome Inhibitor
10%
Overall Survival
10%
Carfilzomib
9%
Stem Cell Transplant
9%
Hematopoietic Cell
8%
Minimal Residual Disease
8%
COVID-19
8%
Randomized Clinical Trial
8%
Adverse Event
8%
Drug Megadose
8%
Peripheral Blood Stem Cell
7%
Stem Cell
6%
Bortezomib
5%
Gene Expression Profiling
5%
Chimeric Antigen Receptor T-Cell Immunotherapy
5%
Transplantation
5%
Malignant Neoplasm
5%
Survival Rate
5%
Autologous Hematopoietic Stem Cell Transplantation
5%
Hematopoietic Stem Cell Transplantation
5%
Monoclonal Antibody
5%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Dexamethasone
28%
Diseases
21%
Lenalidomide
18%
Carfilzomib
17%
Selinexor
16%
Myeloma
15%
Adverse Event
14%
Progression Free Survival
13%
Monoclonal Antibody
13%
Proteasome Inhibitor
12%
Overall Survival
11%
Bortezomib
10%
Pomalidomide
9%
Minimal Residual Disease
8%
Melphalan
8%
Tocilizumab
8%
Observational Study
8%
Thalidomide
7%
Malignant Neoplasm
6%
Survival Rate
6%
Tolerability
5%
